Aldeyra Therapeutics (ALDX) Non-Current Deferred Tax Liability (2019 - 2024)

Aldeyra Therapeutics (ALDX) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $2.2 million in Q4 2024.

• Quarterly Non-Current Deferred Tax Liability fell 50.45% year-over-year to $2.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.2 million (down 50.45% YoY) and the FY2024 annual result came in at $2.2 million, down 50.45% from the prior year.
• Non-Current Deferred Tax Liability slipped to $2.2 million in Q4 2024, from $3.9 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $8.3 million in Q1 2021 to a low of $2.2 million in Q4 2024.
• A 5-year average of $4.0 million and a median of $3.5 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability jumped 241.65% — and 2024, when it slumped 50.45%.
• Tracing ALDX's Non-Current Deferred Tax Liability over 5 years: stood at $4.8 million in 2020, then plunged by 49.85% to $2.4 million in 2021, then increased by 8.37% to $2.6 million in 2022, then surged by 71.34% to $4.5 million in 2023, then tumbled by 50.45% to $2.2 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $2.2 million (Q4 2024), $3.9 million (Q2 2024), and $7.3 million (Q1 2024), per Business Quant data.